What is Lisocabtagene maraleucel?

Lisocabtagene maraleucel (Lisocabtagene maraleucel) is a CD-19-directed chimeric antigen receptor (CAR) T-cell therapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL). Lisocabutagon is only available through a restricted program called Lisocabutagon REMS under the Risk Assessment and Mitigation Strategy (REMS) and can only be administered by intravenous infusion at certified health care facilities.

LargeB-cell lymphoma (LBCL) includes unspecified diffuse largeB-cell lymphoma (DLBCL) (includes DLBCL arising from indolent lymphomas) , high-gradeB-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B in patients with Refractory disease to first-line chemoimmunotherapy or relapse within 12 months; orRefractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and is ineligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or Relapse or refractory disease after two or more systemic treatments. Lisocabeta root is not indicated for the treatment of patients with primary central nervous system (CNS) lymphoma.

Lisocabbutanol may cause serious adverse reactions, including allergic reactions, serious infections, long-term cytopenias, hypogammaglobulinemia, and secondary malignancies. Patients receiving lisocabetagen should avoid driving and engaging in hazardous occupations or activities, such as operating heavy or potentially hazardous machinery, for at least 8 weeks.

Since Lisocaptagen has been on the market for a short time, there may be less information on its price and other related information.